It's too soon to know if the trend will last. But health providers fear the national discourse around vaccines could yield more sickness and death this winter.

TOPEKA (KSNT) – December is a peak month for the spread of respiratory syncytial virus, or RSV, a respiratory virus that ...

You recently posted a couple of articles about the respiratory syncytial virus (RSV) vaccine and the benefits versus the ...

A number of diseases tend to peak in the winter, thanks to indoor gatherings that help germs spread. The list includes not ...

Researchers evaluated the real-world effectiveness of nirsevimab in preventing ICU admission and acute respiratory failure associated with RSV among infants.

Dec 12 (Reuters) - GSK said on Friday a panel of the European Medicines Agency had backed the use of its respiratory ...

GSK (GSK) stock is in focus as an expert panel of the European Medicines Agency ((EMA)) endorses the company's Arexvy RSV ...

A new study has found that a significant percentage of adults in the United States have at least one risk factor for severe respiratory syncytial virus (RSV), even as eligibility for the RSV ...

Federal regulators have begun a safety review of two RSV medicines used to protect infants, even though no safety problems ...

Adjuvants help boost the immune response to the antigen in the vaccine, and can also help with dose sparing, according to a ...

FDA turns up the heat: Federal regulators are requesting more safety information from drugmakers on products meant to protect ...